Bernhard Paul

Drug development / Biotech consultant at Carinth Consulting ( All opinions are my own. (Re)tweets ≠ endorsements.

[Steve Stewart-Williams @SteveStuWill]

This is hilarious

[Matthew Herper @matthewherper]

FDA’s Woodcock to stop drug approval work to focus on Covid-19 vaccines, ⁦@NicholasFlorko⁩ writes. https://t.co/dFgHn35Gu0

[Bernhard Paul @bernhardjpaul]

The Life Science Leader 2020 CDMO Leadership Awards special issue is out and it's always interesting to see who are this year's winners. And in this article, I explain how you can make your CDMO selection an award winning event.
https://t.co/1Ay5QILxxb

[Bernhard Paul @bernhardjpaul]

Ranitidine to be withdrawn from the US market

[FDA Drug Information @FDA_Drug_Info]

⚠️FDA requests market withdrawal of all remaining prescription and OTC ranitidine (Zantac) products on the U.S. market. This means that ranitidine will not be available for use in the U.S. https://t.co/kfcW0wlHo6

[Dani Burger @daniburgz]

Not muting your mic is the new reply all

[Bernhard Paul @bernhardjpaul]

CPhI North America rescheduled to September 2020
#CPhI #CPhINorthAmerica https://t.co/RkNMB2RzZe

[Bernhard Paul @bernhardjpaul]

DCAT Week 2020 Cancelled #DCAT #dcatweek2020 #dcatweek https://t.co/DgvdKMtZ3Q

[Eric Topol @EricTopol]

Heart disease was on track to be overtaken by #cancer as the leading cause of death in the US. Then something(s) changed
https://t.co/eVmO8S14My @betswrites @CDCgov data

[Bernhard Paul @bernhardjpaul]

Why is institutional knowledge important and how could it affect your project? The final part of my series for Outsourced Pharma discusses the impact of losing key staff. 5 Questions To Ask Your CDMO: #5 — What Is Your Employee Turnover? https://t.co/FsAlRP0008

[Andy Biotech @AndyBiotech]

#Biotech chart of the day

This chart of cumulative sales of oncology drugs nicely captures a big part of biotech history

Unfortunately very few drugs will be able to enjoy long life cycle of monopoly in the current over-competitive environment like Avastin/Herceptin/Rituxan did

[Lisa Jarvis @lisamjarvis]

Last year brought a new high for FDA drug approvals: 59!! Come tool around our fun interactive table & check out all the pretty small molecules (all 38 of 'em!): https://t.co/zLRxYirsBA

[Bernhard Paul @bernhardjpaul]

Many companies perform with maximum efficiency when they operate in areas where they have the most experience. Part 4 of my series for Outsourced Pharma discusses the importance of matching your project needs with your partner's core expertise. https://t.co/yOWWz3h2ju

[BioSpace @biospace]

#Vertex's Triple-Combo CF Drugs Dazzle in Preliminary Data from 2 Phase III Trials https://t.co/z9kGo6gTe5 #ClinicalTrials #Pharma

[Bernhard Paul @bernhardjpaul]

The majority of drug candidates developed today face bioavailability challenges. Part 3 of my series for Outsourced Pharma discusses several approaches to increase solubility and what questions you should ask your potential partner. https://t.co/C8zaNsKJQa

[Bernhard Paul @bernhardjpaul]

@PeterAtNotch @Stream_Bio Congratulations Peter! 🍾👍

[Bernhard Paul @bernhardjpaul]

How does your CDMO deal with the inevitable problems during drug development? Part 2 of my series for Outsourced Pharma explores the difficult topic of problems and failures. #outsourcing #drugdevelopment https://t.co/xN6E7a9Lva

[Chemistry World @ChemistryWorld]

Healthcare review body the Cochrane Collaboration is in turmoil after one board member was expelled and another four resigned in protest https://t.co/BeVqdJbtcF

[SCI Fine Chemicals @SCIFineChem]

We'll be in Belgium next week for a Celebration of Organic Chemistry. Looking forward to seeing @crjsteph @RhPdCu @Vy_Dong_Group @allanjbwatson @ITC_Cambridge @NoelGroupTUE @ListLaboratory @GouverneurGroup @morandilab there! #orgchem2018 #gettingexcited

[Forbes Health @forbeshealth]

Venture capital is flowing into biotech, valuations are up across the board, and deal terms are “looser” than they’ve ever been https://t.co/dfgpA3s7uj by @LifeSciVC

[John Carroll @JohnCendpts]

Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
https://t.co/SDEZSGaaAt